March 25, 2026
Frederick, MD – Jecho Laboratories, Inc. will present emerging preclinical data on JLC062, a novel B7-H3/PD-L1 bispecific antibody drug conjugate (bsADC) at the American Association for Cancer Research (AACR) Annual Meeting 2026. B7-H3 is a tumor-associated antigen highly expressed in solid tumors, while PD-L1 plays a key role in suppressing immune responses. JLC062 is composed of a fast-internalizing anti-B7-H3 arm and a non-internalizing anti-PD-L1 arm, which enables targeted delivery of a cytotoxic payload to tumors and disrupts immunosuppressive signaling while minimizing toxicity to immune cells. JLC062 is a promising therapeutic modality that integrates immune checkpoint inhibition with targeted cytotoxic delivery that may yield deep and durable antitumor responses.
The AACR Annual Meeting will be held April 17-22, 2026 in San Diego, CA.
Details on the presentation are below. The full abstract can be found on the AACR website.
Abstract 6561 /27: Rational design of a B7-H3/PD-L1 bsADC combining checkpoint blockade with targeted cytotoxicity for improved antitumor efficacy
- Session Name: Clinical Research Track, Immune Checkpoint Blockade, PO.CL05.04
- Session Time: Tuesday, April 21, 2026 2 – 5 p.m. PST
- Location: San Diego Convention Center, Poster Section 44